This project will develop solutions to help overcome barriers to living kidney donor transplantation. It will also evaluate the impact of these solutions on patient experiences, outcomes and health care system costs.
In partnership with Indigenous patients and families who have or are affected by CKD, we will work together in participating communities to develop a unique suite of educational approaches for treatment options for failing kidneys specifically for the Indigenous population.
This research project aims to understand how we can empower patients to self-manage their chronic kidney disease to improve disease progression and overall patient experience and well-being.
Patients on hemodialysis take 12 medications per day on average. This project will develop tools to help reduce the use of medications that lack evidence for effectiveness and safety in hemodialysis patients.
New technologies make it possible for patients to communicate with their health professionals and manage their own health information. Our team of patients, researchers, clinicians and health care decision-makers will reinvent kidney care to reflect the needs and capabilities of patients in the 21st century.
Evidence suggests that patient-reported outcomes measures (PROMs) have a positive impact in clinical practice; however, the impact on health outcomes and experiences is not fully understood. This research aims to fill this gap by evaluating the impact of routinely measuring and reporting patient-reported experience and outcomes, clinical outcomes, and healthcare utilization.
Evaluation of sodium deposition in soft tissues of patients with kidney disease and its association with patient symptomatologyGraham2018-08-01T16:38:39-07:00
This study will try to examine sodium deposition in the skin, muscle and bones of patients with different kidney function and different dialysis modalities and its association with symptoms.
Gabapentin and pramipexole are commonly used drugs for several conditions and are known to reduce restless legs in patients who do not have kidney disease. The results of DISCO will determine whether gabapentin, pramipexole, or both should be offered to patients receiving dialysis who suffer from restless legs.
Spironolactone is a drug that is very effective at reducing scarring of the heart and might help prevent heart-related deaths in patients with kidney failure. We will determine if spironolactone reduces heart related deaths and hospitalizations due to heart failure.
Advances in ADPKD research have identified a number of promising therapeutic drugs. Several of these drugs are re-purposed compounds that are currently approved for diseases other than ADPKD. We plan to perform two pilot control trials of two of these therapeutic drugs to test the impact on ADPKD patients and to evaluate their potential.